Neurodawn Pharmaceutical Co., Ltd.
Registry sponsor category
Industry
- Other names
- Neurodawn Pharmaceutical Co., Ltd.
- Company name
- Neurodawn Pharmaceutical Co., Ltd.
- Organisation type
- Industry
- Registry sponsor category
- Industry
- Publicly traded (proxy)
- No
- Listing at source
- Listed
Related records
Trials (19)
- A Phase 1 Study of Y-3 in US Healthy Volunteers.
- Cilostazol Dexborneol Versus Placebo for Microcirculation Dysfunction After Reperfusion Therapy in Patients With Acute Ischemic Stroke With Large Vessel Occlusion
- EFfects of Y-6 SUblingual Tablets foR PaTients With AcUte Ischemic StRokE (FUTURE)
- Efficacy and Safety of Minocycline in Patients With Moderate to Severe Acute Ischemic Stroke
- Efficacy and Safety of Sarecycline in Patients With Acute Ischemic Stroke After Reperfusion Therapy
- ND-12 Combined With H-6 for Adult Chronic Inflammatory Diarrhea
- Pharmacokinetic Effect of Y-3 for Injection on Rosuvastatin Calcium Tablets in Healthy Participants
- Pharmacokinetic Effect of Y-3 on Repaglinide，Warfarin and Omeprazole in Healthy Participants
- Pharmacokinetics of Y-4 Tablets With Pregabalin Capsules and Riluzole Tablets in Chinese Healthy Subject
- Pharmacokinetics of Y-4 Tablets With Pregabalin Capsules and Riluzole Tablets in U.S. Healthy Participants
- RK-4 Intracalvariosseous Injection in Treatment of Acute Large Hemispheric Infarction
- Safety and Pharmacokinetics of Y-4 Tablets in Healthy Subjects
- To Evaluate the Effect of Food on the Pharmacokinetics of Y-4 Tablets in Healthy Subjects
- Y-3 for Injection in Patients With Hepatic Insufficiency and Healthy Subjects
- Y-3 for Injection in the Treatment of Acute Ischemic Stroke
- Y-3 Injection in the Treatment of Acute Ischemic Stroke Phase II Clinical Trial
- Y-4 to Treat the Postherpetic Neuralgia
- Y-6 Sublingual Tablets for Acute Penetrating Artery Infarction
- Y-6 Sublingual Tablets for Patients With Acute Ischemic Stroke